Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

COSENTYX 150 MG

SECUKINUMAB : 150 MG · DIN 02438070 · NOVARTIS PHARMACEUTICALS CANADA INC

Health Canada status: MARKETED

COSENTYX 150 MG SOLUTION - DIN 02438070
COSENTYX — DIN 02438070. Product photograph held by Nexara Health.

What is COSENTYX?

COSENTYX 150 MG contains SECUKINUMAB : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02438070, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 10-Apr-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is COSENTYX used for?

Adults: Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Hidradenitis Suppurativa. Pediatrics (6+): Plaque psoriasis, ERA, JPsA.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02438070
Brand nameCOSENTYX
Generic / active ingredientSECUKINUMAB : 150 MG
ManufacturerNOVARTIS PHARMACEUTICALS CANADA INC
Strength150 MG
Dosage formSOLUTION
Route of administrationSUBCUTANEOUS
ScheduleSchedule D
ATC codeL04AC10 SECUKINUMAB
AHFS class90:24.20.92
BiosimilarNo
Health Canada statusMARKETED
Status date10-Apr-2015
Original market date2015-04-10 00:00:00

How is it administered?

Subcutaneous injection. Adult Psoriasis: 300 mg at Weeks 0, 1, 2, 3, 4, then monthly. PsA/AS: 150 mg (consider 300 mg if inadequate response) at Weeks 0, 1, 2, 3, 4, then monthly.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 2-8°C (implied by biological nature and standard handling, though specific range text was cut off in provided snippet). Visually inspect for particles/discoloration.

How is it supplied?

75 mg/0.5 mL PFS; 150 mg/1 mL PFS or SensoReady pen; 300 mg/2 mL PFS or UnoReady pen. Cartons of 1 or 2 units.

Contraindications

Severe hypersensitivity reactions to secukinumab or to any of the components.

Warnings and precautions

Risk of infections (TB, HBV), inflammatory bowel disease, serious hypersensitivity reactions, and severe eczematous eruptions. Evaluate for TB and HBV prior to initiation.

What can be used instead?

Other Canadian products sharing ATC code L04AC10 SECUKINUMAB. 5 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
COSENTYX150 MGSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02547724
COSENTYX300 MG / 2 MLSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02529653
COSENTYX300 MG / 2 MLSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02529661
COSENTYX75 MG / 0.5 MLSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02525569
COSENTYX150 MGPOWDER FOR SOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCAPPROVEDDIN 02438062

Who else supplies SECUKINUMAB worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. SECUKINUMAB appears in 69 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for COSENTYX

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for COSENTYX

Health Canada Drug Product Database (DPD), DIN 02438070. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.